BlossomHill Therapeutics, Inc., a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the closing of a $100 million Series B financing round. The round was led by Colt Ventures with participation from new and existing investors, including Cormorant Asset Management, OrbiMed, Vivo Capital, Hercules BioVentures Partners LLC, Plaisance Capital Management LLC and H&D Asset Management, among others.

Bloomhill Therapeutics，Inc.，一家专注于设计和开发用于治疗癌症和自身免疫性疾病的小分子药物的生物技术公司，今天宣布结束一轮1亿美元的B系列融资。本轮投资由Colt Ventures牵头，新的和现有的投资者参与，包括Cormorant Asset Management、OrbiMed、Vivo Capital、Hercules BioVentures Partners LLC、Plaisance Capital Management LLC和H＆D Asset Management等。

In conjunction with the financing round, Sundeep Agrawal, M.D., General Partner at Colt Ventures, and Timothy Stubbs, M.D., Principal at Vivo Capital, will join the BlossomHill Board of Directors.

结合融资回合，Colt Ventures的普通合伙人Sundeep Agrawal医学博士和维梧资本的负责人Timothy Stubbs医学博士将加入Bloomhill董事会。

This financing brings the total capital raised by the company to $173 million. BlossomHill will use the proceeds to advance its pipeline of multiple in-house discovery and development programs for multiple high-need cancers and autoimmune diseases into the clinic.

此次融资使该公司筹集的总资本达到1.73亿美元。Bloomhill将利用这些收益推进其针对多种高需求癌症和自身免疫性疾病的多个内部发现和开发项目进入诊所。

“We appreciate the strong support from our new and existing investors in this round of financing,” said J. Jean Cui, Ph.D., President and Chief Executive Officer of BlossomHill Therapeutics. “This will be a pivotal year for BlossomHill as we move our first two oncology programs into phase 1 clinical trials, advance several programs forward to IND enabling studies, and continue to build our already very deep pipeline of oncology and autoimmune discovery programs.”.

Bloomhill Therapeutics总裁兼首席执行官J.Jean Cui博士表示：“我们感谢新老投资者在这一轮融资中的大力支持。”“这将是Bloomhill的关键一年，因为我们将前两个肿瘤学项目转入第一阶段临床试验，将几个项目推进IND使能研究，并继续建立我们已经非常深入的肿瘤学和自身免疫发现项目。”

BlossomHill is a drug design company redefining precision medicine to make a leap forward in life expectancy and quality of life for patients, creating novel chemical entities that seek to address on- and off-target resistance mechanisms. Combining human intelligence, creative thinking, and proven drug design expertise, the company is developing small molecules with the potential to redefine the gold standard for cancer and autoimmune disease treatment.

Bloomhill是一家重新定义精准医学的药物设计公司，旨在提高患者的预期寿命和生活质量，创建新型化学实体，寻求解决靶向和非靶向耐药机制。结合人类智慧、创造性思维和成熟的药物设计专业知识，该公司正在开发具有重新定义癌症和自身免疫性疾病治疗金标准潜力的小分子。

“It is a privilege to partner with Dr. Jean Cui and her team at BlossomHill. We have been highly impressed with her drug design capabilities and the innovative pipeline she has built,” said Sundeep Agrawal, M.D., General Partner at Colt Ventures. “Jean has an outstanding track record of designing three FDA-approved cancer drugs, and we look forward to supporting the company’s next phase of development.”

Colt Ventures的普通合伙人Sundeep Agrawal医学博士说：“很荣幸能与Jean Cui博士及其团队在Bloomshill合作。她的药物设计能力和她建立的创新管道给我们留下了深刻印象。”。“Jean在设计三种FDA批准的抗癌药物方面有着出色的业绩记录，我们期待着为公司的下一阶段开发提供支持。”

BlossomHill was co-founded in June 2020 by renowned drug designer and chemist Dr. Jean Cui, who is responsible for the design of the FDA-approved drugs crizotinib (XALKORI®), lorlatinib (LOBRENA®) and repotrectinib (AUGTYRO®) and biotech business veteran, Y. Peter Li, Ph.D., M.B.A.; Dr. Cui and Dr. Li were also the co-founders of Turning Point Therapeutics, Inc., which was acquired by Bristol Myers Squibb in June 2022.

Bloomhill于2020年6月由著名的药物设计师和化学家Jean Cui博士共同创立，他负责设计FDA批准的药物克唑替尼（XALKORI®），洛拉替尼（LOBRENA®）和repotrectinib（AUGTYRO®）以及生物技术商业老手Y.Peter Li博士（M.B.A.）。；崔博士和李博士也是转折点治疗公司的联合创始人，该公司于2022年6月被百时美施贵宝收购。

“We are excited to continue to support BlossomHill Therapeutics’ creative, trailblazing drug development team in its mission of bringing potentially best-in-class drug treatment to meaningfully improve patient lives,” said Bihua Chen, Founder of Cormorant Asset Management.

鸬鹚资产管理公司创始人陈碧华（Bihua Chen）表示：“我们很高兴继续支持Bloomhill Therapeutics创造性、开拓性的药物开发团队，为其带来潜在的同类最佳药物治疗，以有意义地改善患者生活。”

“Since its founding, the company has made rapid progress on its drug discovery programs, and we look forward to the generation of clinical data as BlossomHill enters its next phase,” added Carl Gordon, Ph.D., Managing Partner, OrbiMed Advisors.

“自成立以来，该公司在药物发现计划方面取得了快速进展，随着Bloomhill进入下一阶段，我们期待着临床数据的产生，”OrbiMed Advisors管理合伙人卡尔·戈登博士补充道。

About BlossomHill Therapeutics

关于Bloomhill Therapeutics

BlossomHill Therapeutics, Inc. is a small molecule drug design and development company focused on addressing unmet medical needs in oncology and autoimmune diseases. The company is building a deep pipeline of candidates across a range of targets with the aim of making the next leap forward in treatment for patients.

Bloomhill Therapeutics，Inc.是一家小分子药物设计和开发公司，专注于解决肿瘤学和自身免疫性疾病中未满足的医疗需求。该公司正在一系列目标上建立一个深入的候选人渠道，目的是在患者治疗方面取得下一个飞跃。

The company’s approach to drug design and development first considers the medical need through deep knowledge of the science behind the disease, and then seeks to design a novel chemotype to provide the best chance of success. Headquartered in San Diego, California, BlossomHill Therapeutics is supported by a strong syndicate of leading investors, including Cormorant Asset Management, OrbiMed, Vivo Capital and Colt Ventures.

该公司的药物设计和开发方法首先通过对疾病背后科学的深入了解来考虑医疗需求，然后寻求设计一种新型化学型以提供最佳的成功机会。Bloomhill Therapeutics总部位于加利福尼亚州圣地亚哥，由领先投资者组成的强大财团提供支持，包括Cormorant Asset Management、OrbiMed、Vivo Capital和Colt Ventures。